The current study presents a new set of signs of PCa with a large effect size that deserves more attention in both clinicians and researchers in order to improve the detection of prostate cancers.
About 14,400 men will have prostate cancer in their lifetimes, but only 2,700 will succumb to it. Prostate cancer is on the rise in the United States.
There was no correlation between patient age (mean age: 51.5 yr) or biopsy Gleason score (mean 7.2) and prostate cancer-specific mortality; only the serum PSA level at diagnosis was a significant predictor of prostate cancer-specific mortality.
Risk factors for prostate cancer include age, genetics and diet. However, these risks are not completely known, and prostate cancer is caused by random genetic mutations. The effects of aging on prostate cancer development are complex and not fully understood.
Prostate cancer is the third-most common cancer in men and accounts for 8% of all cancers in men. It is a disease of the male genital system. It is the second-leading cause of cancer mortality (cancer deaths) among men, following lung cancer. The prostate is an organ of the male reproductive system and forms part of the lower urinary tract.\n
The treatment options for [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer), as listed by the National Comprehensive Cancer Network are summarized here, although additional treatment options exist for prostate cancer that has metastasized. The most commonly recommended treatment options for stage I-IIa prostate cancer are external-beam radiation therapy, hormonal therapy, and external beam radiation therapy combined with pelvic lymph node dissection. For those with either T3 or T4 prostate cancer there are a variety of suggested treatment options; however, it is recommended that patients discuss treatment options with their clinician. The overall 5-year survival rate for prostate cancer is 80-90%. The National Comprehensive Cancer Network lists several treatment options for those who have either locally recurrent prostate cancer or have metastatic disease.
The seriousness of [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) can vary among different patients and also among different geographic regions. The probability of dying from prostate cancer increases from 15% to 36% if the cancer escapes treatment during the early stage of the disease.
Radiation therapy is commonly given to men with LUTS or lower urinary tract cancers with the hope of improving symptoms. Yet some patients also have good outcomes with radiation therapy in terms of the risk of recurrence of their disease.
The survival for prostate cancer patients depends on the stage at diagnosis, aggressiveness of the disease, surgical resectability, age, Gleason score, seminal vesicle extension, race, and hormonal therapy. Prostate cancer is curable in about half of all patients and it seems that prostate cancer can be controlled in most patients when properly treated. Men with Stage T1 prostate cancer are at high risk for early death from the disease, whereas those with Stage T4 prostate cancer have a very high risk for death from metastatic disease. Women of all ages usually have a much higher mortality from prostate cancer.
Despite our efforts, we were limited by the paucity of data on the long-term oncologic status of [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) in this group of patients. However, the overall rate of metastasis was lower than in other series. This demonstrates a favorable outlook for men treated with radical prostatectomy alone.
The average age at diagnosis in the West is 67.8. In Australia the average age at diagnosis is 65.1, and in Scotland was 65.8 for men less than 70.